ContraVir Pharmaceuticals to Present Three Posters at AASLD 2017 and Participate in the Search for HBV / HDV Cure Analyst Day

EDISON, N.J., Oct. 12, 2017 -- ContraVir Pharmaceuticals, Inc. (NASDAQ:CTRV), a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced today it will participate in an analyst day event sponsored by the Liver Institute and Foundation for Education and Research (LIFER) titled, “The Search for HBV / HDV Cure.” The event will take place on Friday, October 20, 2017, between 8-00am-2:00pm at the Ritz-Carlton, Pentagon City. Invited attendees will include companies in HBV and HDV drug development, research analysts and selected academics.

Dr. John-Sullivan-Bolyai, M.D., MPH, Chief Medical Officer and Robert Foster, Pharm.D., Ph.D., Chief Scientific Officer of ContraVir will be participating in two panel discussions with colleagues discussing advances in HBV and HDV cure.

As previously announced, ContraVir will be presenting three poster presentations the following day at AASLD, The Liver Meeting®, in Washington, DC.

Poster #1: "Pharmacokinetics, Safety and Antiviral Activity of Tenofovir exalidex (TXL), A Novel Prodrug of Tenofovir, Administrated as Ascending Multiple Doses to HBV-Infected Subjects: A 28 Day Study Final Analyses"
Publication Number: 943
Date and Time: October 21, 2017 from 2:00 PM to 7:30 PM 
Session: Hepatitis B: New and Approved Treatment 
Location: Washington Convention Center, Hall D 

Poster #2:"Independent and Combinational Anti-HBV Effects of CRV431 and TXL in the HBV Transgenic Mouse Model"
Publication Number: 907 
Date and Time: October 21, 2017 from 2:00 PM to 7:30 PM 
Session: Hepatitis B: New and Approved Treatment 
Location: Washington Convention Center, Hall D 

Poster #3:"CRV431 Blocks NTCP-Mediated Uptake of HBV and HDV Independently of Effects on Bile Acid Transport"
Publication Number: 928 
Date and Time: October 21, 2017 from 2:00 PM to 7:30 PM 
Session: Hepatitis B: New and Approved Treatment 
Location: Washington Convention Center, Hall D 

ContraVir’s poster presentations from AASLD 2017 will be available on the company’s website following their disclosure at the meeting at http://ir.contravir.com/events-and-presentations/presentations. For further information about the 2017 AASLD meeting visit: https://www.aasld.org/events-professional-development/liver-meeting.

About ContraVir Pharmaceuticals

ContraVir is a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies with a specific focus on developing a potentially curative therapy for hepatitis B virus (HBV). The Company is developing two novel anti-HBV compounds with complementary mechanisms of action. TXL™ currently in Phase 2a, is designed to deliver high intrahepatic concentrations of TFV, while minimizing off-target effects caused by high levels of circulating TFV. CRV431, the other anti-HBV compound, is a next-generation cyclophilin inhibitor with a unique structure that increases its potency and selective index against HBV. ContraVir is also developing Valnivudine™, an orally available nucleoside analogue prodrug; Valnivudine™ is currently in Phase 3 for the treatment of herpes zoster. In addition to direct antiviral activity, Phase 2 data suggest that Valnivudine™ has the potential to reduce the incidence of debilitating shingles-associated pain known as post-herpetic neuralgia (PHN). For more information visit www.contravir.com.

Forward Looking Statements

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as "anticipate," "believe," "forecast," "estimated" and "intend," among others. These forward-looking statements are based on ContraVir's current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, substantial competition; our ability to continue as a going concern; our need for additional financing; uncertainties of patent protection and litigation; uncertainties with respect to lengthy and expensive clinical trials, that results of earlier studies and trials may not be predictive of future trial results; uncertainties of government or third party payer reimbursement; limited sales and marketing efforts and dependence upon third parties; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. As with any drug candidates under development, there are significant risks in the development, regulatory approval, and commercialization of new products. There are no guarantees that future clinical trials discussed in this press release will be completed or successful, or that any product will receive regulatory approval for any indication or prove to be commercially successful. ContraVir does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in ContraVir's Form 10-K for the year ended June 30, 2017 and other periodic reports filed with the Securities and Exchange Commission.

For further information, please contact:

Sharen Pyatetskaya
Director of Investor Relations
[email protected]; (732) 902-4028